Biochemical and Biophysical Research Communications
Regular ArticleImmuno-Localization of H+/Peptide Cotransporter in Rat Digestive Tract☆
Abstract
In the mammalian digestive tract, small peptides are absorbed by a H+-coupled peptide transport system. Using an antibody against the rat H+/peptide constransporter (PepT1), we examined the localization of PepT1 immunohistochemically along the rat digestive tract. PepT1 was detected in the small intestine (duodenum, jejunum, and ileum), but not in the esophagus, stomach, colon, or rectum. PepT1 was especially enriched in the villi, where it was localized at the brush border of the absorptive epithelial cells. PepT1 was not detected in the mucus-secreting goblet cells or less-differentiated epithelial cells in the crypts. These observations show that PepT1 is specific to the brush border of the differentiated absorptive epithelial cells and suggest that H+-coupled uptake of small peptides and peptide-like drugs occurs at the apical membrane of these cells in the small intestine.
References (0)
Cited by (216)
Effects of L-Leu-L-Leu peptide on growth, proliferation, and apoptosis in broiler intestinal epithelial cells
2024, Poultry ScienceSmall peptides are nutrients and bioactive molecules that have dual regulatory effects on nutrition and physiology. They are of great significance for maintaining the intestinal health and production performance of broilers. We here cultured the primary small intestinal epithelial cells (IEC) of chicken in a medium containing L-Leu (Leu) and L-Leu-L-Leu (Leu-Leu) for 24 h. The untreated cells were considered as the control group. The growth, proliferation, and apoptosis of IEC were examined. By combining RNA-seq and label-free sequencing technology, candidate genes, proteins, and pathways related to the growth, proliferation, and apoptosis of IEC were screened. Immunofluorescence detection revealed that the purity of the isolated primary IEC was >90%. The Leu-Leu group significantly promoted IEC growth and proliferation and significantly inhibited IEC apoptosis, and the effect was better than those of the Leu and control groups. Using transcriptome sequencing, four candidate genes, CCL20, IL8L1, IL8, and IL6, were screened in the Leu group, and one candidate gene, IL8, was screened in the Leu-Leu group. Two candidate genes, IL6 and RGN, were screened in the Leu-Leu group compared with the Leu group. Nonquantitative proteomic marker sequencing results revealed that through the screening of candidate proteins and pathways, found one growth-related candidate protein PGM3 and three proliferation-related candidate proteins RPS17, RPS11, and RPL23, and two apoptosis-related candidate proteins GPX4 and PDPK1 were found in the Leu-Leu group compared with Leu group. In short, Leu-Leu could promote IEC growth and proliferation and inhibit IEC apoptosis. On combining transcriptome and proteome sequencing technologies, multiple immune- and energy-related regulatory signal pathways were found to be related to IEC growth, proliferation, and apoptosis. Three candidate genes of IL8, IL6, and RGN were identified, and six candidate proteins of PGM3, RPS17, RPS11, RPL23, GPX4, and PDPK1 were involved in IEC growth, proliferation, and apoptosis. The results provide valuable data for preliminarily elucidating small peptide-mediated IEC regulation pathways, improving the small peptide nutrition theoretical system, and establishing small peptide nutrition regulation technology.
Establishment of SLC15A1/PEPT1-Knockout Human-Induced Pluripotent Stem Cell Line for Intestinal Drug Absorption Studies
2020, Molecular Therapy Methods and Clinical DevelopmentBecause many peptide and peptide-mimetic drugs are substrates of peptide transporter 1, it is important to evaluate the peptide transporter 1-mediated intestinal absorption of drug candidates in the early phase of drug development. Although intestinal cell lines treated with inhibitors of peptide transporter 1 are widely used to examine whether drug candidates are substrates for peptide transporter 1, these inhibitors are not sufficiently specific for peptide transporter 1. In this study, to generate a more precise evaluation model, we established peptide transporter 1-knockout induced pluripotent stem cells (iPSCs) by using a CRISPR-Cas9 system and differentiated the cells into intestinal epithelial-like cells. The permeability value and uptake capacity of glycylsarcosine (substrate of peptide transporter 1) in peptide transporter 1-knockout intestinal epithelial-like cells were significantly lower than those in wild-type intestinal epithelial-like cells, suggesting that peptide transporter 1 was successfully depleted in the epithelial cells. Taken together, our model can be useful in the development of peptide and peptide-mimetic drugs.
Anatomy and Physiology of the Duodenum
2019, Shackelford's Surgery of the Alimentary Tract: 2 Volume SetAlthough spanning only 20 to 30 cm, from the pylorus to the ligament of Treitz, the duodenum is the “gate” that controls the passage of food from the stomach to the jejunum. The name is derived from the Latin phrase intestinum duodenum digitorum, or “intestine of twelve digits.” This Latin phrase may have derived from the writings of the Greek physician Herophilus (334–280 bc). Although it is the shortest segment of small bowel, the duodenum is the initial site of contact for gastric secretions, bile, and digestive enzymes from the common bile duct and the pancreas. Thus it plays an important role in the regulation of digestion, absorption of essential micronutrients and macronutrients, and bowel motility. Its relationships to the major structures of the upper abdomen lend it to exposure during a large number of gastrointestinal surgical interventions. As such, it is important to understand both the structure and function of the duodenum as it relates to alimentary surgery.
Intestinal absorption and activation of decitabine amino acid ester prodrugs mediated by peptide transporter PEPT1 and enterocyte enzymes
2018, International Journal of PharmaceuticsDecitabine (DAC), a potent DNA methyltransferase (DNMT) inhibitor, has a limited oral bioavailability. Its 5′-amino acid ester prodrugs could improve its oral delivery but the specific absorption mechanism is not yet fully understood. The aim of this present study was to investigate the in vivo absorption and activation mechanism of these prodrugs using in situ intestinal perfusion and pharmacokinetics studies in rats. Although PEPT1 transporter is pH dependent, there appeared to be no proton cotransport in the perfusion experiment with a preferable transport at pH 7.4 rather than pH 6.5. This suggested that the transport was mostly dependent on the dissociated state of the prodrugs and the proton gradient might play only a limited role. In pH 7.4 HEPES buffer, an increase in Peff was observed for L-val-DAC, D-val-DAC, L-phe-DAC and L-trp-DAC (2.89-fold, 1.2-fold, 2.73-fold, and 1.90-fold, respectively), compared with the parent drug. When co-perfusing the prodrug with Glysar, a known substrate of PEPT1, the permeabilities of the prodrugs were significantly inhibited compared with the control. To further investigate the absorption of the prodrugs, L-val-DAC was selected and found to be concentration-dependent and saturable, suggesting a carrier-mediated process (intrinsic Km: 7.80 ± 2.61 mM) along with passive transport. Determination of drug in intestinal homogenate after perfusion further confirmed that the metabolic activation mainly involved an intestinal first-pass effect. In a pharmacokinetic evaluation, the oral bioavailability of L-val-DAC, L-phe-DAC and L-trp-DAC were nearly 1.74-fold, 1.69-fold and 1.49-fold greater than that of DAC. The differences in membrane permeability and oral bioavailability might be due to the different stability in the intestinal lumen and the distinct PEPT1 affinity which is mainly caused by the stereochemistry, hydrophobicity and steric hindrance of the side chains. In summary, the detailed investigation of the absorption mechanism by in vivo intestinal perfusion and pharmacokinetic studies showed that the prodrugs of DAC exhibited excellent permeability and oral bioavailability, which might be attributed to a hybrid (partly PEPT1-mediated and partly passive) transport mode and a rapid activation process in enterocytes.
Peptide transporter 1 (PepT1)in fish: A review
2017, Aquaculture and FisheriesThe Peptide Transporter 1 (PepT1) plays an important role in animal protein nutrition. This is a low-affinity/high-capacity, stereoselective transmembrane transporter that mediates the uptake of a fraction of dietary amino acids in their di- and tripeptide forms. PepT1 is highly expressed in the intestines of vertebrates and the current studies examining PepT1 function have concentrated mostly on mammals and less emphasis has been placed on protein nutrition in fish. In the gastrointestinal track, amino acids are absorbed more efficiently in the form of small peptides than as free amino acids suggesting a potential role of PepT1 in the optimization of amino acid absorption which is relevant for fish nutrition. Therefore, this review focused on the physiological characteristics, structures, tissue distribution and expression of PepT1 transcripts and regulation of PepT1 protein in fish.
Oral absorption basics: Pathways and physicochemical and biological factors affecting absorption
2017, Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice: Second EditionTo be effective, drugs in an oral dosage form first must be absorbed and then reach the target organs via systemic circulation. Barriers that prevent drugs from reaching the systemic circulation are called bioavailability barriers, which influence the nature and intensity of an oral drug’s therapeutic activity. Chief among these barriers are called the first-pass metabolism, which is mainly mediated by the first-pass metabolism organs (the liver and the intestine). First-pass metabolism of oral drugs in the liver and the intestine can be mediated by phase I and phase II enzymes, as well as efflux transporters. Together, these disposition processes play the predominant role in determining the biological fate of drugs before they reach the site of action. On the other hand, the physicochemical factors of drugs and pathophysiological conditions of patients could also significantly affect the absorption of drugs. Recently, pharmacogenomics (ie, genetic variations in relevant enzymes and efflux transporters) are playing an ever-greater role in so-called individualized or precision medicine. Thus, this chapter addresses major absorption, metabolism, and elimination pathways of drugs, as well as the physicochemical and physiological factors affecting drug absorption.
- ☆
Abbreviations: PMSF, phenylmethanesulfonyl fluoride; PBS, phosphate-buffered saline; TBS, Tris-buffered saline; TBS-T, Tris-buffered saline containing 0.1% Tween 20; DAPI, 4′,6-diamidino-2-phenylindole dihydrochloride.
- 1
Mailing address: Laboratory of Molecular and Cellular Morphology, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Gunma 371, Japan. E-mail: [email protected].